AdvaMed Seeks More Safeguards For Distributing Off-Label Journal Articles
This article was originally published in The Gray Sheet
Executive Summary
The device industry wants more protection than that supplied in draft FDA guidance on appropriate dissemination of journal articles for studies of non-approved product uses, while some members of Congress believe distribution of off-label study information should be banned outright